<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538041</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-206</org_study_id>
    <secondary_id>Parsaclisib</secondary_id>
    <nct_id>NCT03538041</nct_id>
  </id_info>
  <brief_title>A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia</brief_title>
  <official_title>A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of parsaclisib administered&#xD;
      orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin&#xD;
      and evidence of ongoing hemolysis that requires treatment intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants attaining a complete response (CR)</measure>
    <time_frame>Week 6 to Week 12</time_frame>
    <description>CR defined as hemoglobin &gt; 12 g/dL not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants attaining a partial response (PR)</measure>
    <time_frame>From Baseline to Week 6 to Week 12</time_frame>
    <description>PR defined as hemoglobin 10-12 g/dL or at least ≥ 2 g/dL increase from baseline not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a treatment-emergent adverse event (TEAE)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants attaining a CR during post baseline visits</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>CR defined as hemoglobin &gt; 12 g/dL not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants attaining a PR during post baseline visits</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>PR defined as hemoglobin 10-12 g/dL or at least ≥ 2 g/dL increase from baseline not attributed to transfusion effect and the normalization of hemolytic markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants attaining an increase in hemoglobin from baseline</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>Participants attaining a ≥ 2 g/dL increase in hemoglobin from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of hemoglobin</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>Hemoglobin level will be monitored throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring transfusions</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>Transfusion requirements will be monitored throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve normalization of hemolytic markers</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Hemolysis markers include hemoglobin, haptoglobin, LDH, reticulocyte count, total bilirubin, and direct/indirect bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of daily usage of prednisone</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>Prednisone use will be monitored throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) sub-scale questionnaire</measure>
    <time_frame>From Baseline up to 28 weeks</time_frame>
    <description>FACIT-F will be used to assess changes in patient-reported outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <description>Parsaclisib administered orally.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of AIHA based on the presence of hemolytic anemia and serological evidence&#xD;
             of anti-erythrocyte antibodies, detectable by the direct antiglobulin test.&#xD;
&#xD;
          -  Participants who have disease progression after treatment with standard therapies that&#xD;
             are known to confer clinical benefit, or who are intolerant to treatment, or who&#xD;
             refuse standard treatment. There is no limit to the number of prior treatment&#xD;
             regimens.&#xD;
&#xD;
          -  Hemoglobin 7 to 10 g/dL.&#xD;
&#xD;
          -  No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying&#xD;
             conditions.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 to 2.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Concurrent conditions and history of other protocol-specified diseases.&#xD;
&#xD;
          -  ANC &lt; 1.5 × 10^9/L.&#xD;
&#xD;
          -  Platelet count &lt; 100 × 10^9/L.&#xD;
&#xD;
          -  Severely impaired liver function.&#xD;
&#xD;
          -  Impaired renal function with estimated creatinine clearance less than 45 mL/min.&#xD;
&#xD;
          -  Anti-phospholipid antibodies positive or elevated anti-streptolysin antibodies.&#xD;
&#xD;
          -  Positive serology test results for hepatitis B surface antigen or core antibody, or&#xD;
             hepatitis C virus antibody with detectable RNA at screening, consistent with active or&#xD;
             chronic infection.&#xD;
&#xD;
          -  Known HIV infection or positivity on immunoassay.&#xD;
&#xD;
          -  History or presence of an abnormal ECG that, in the investigator's opinion, is&#xD;
             clinically meaningful.&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to parsaclisib or its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Butler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health System Inc., Dba the University of Tn Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>01090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire (Chru) de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Hopital de La Timone</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Ca Granda Ospedale Maggiore</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITï¿½ DI NAPOLI FEDERICO II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITï¿½ DI NOVARA</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>phosphatidylinositol 3-kinase (PI3K) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

